Monoferric moments

Hi, I'm John Ogden, PharmD and welcome to Monoferric Moments.

For the last 14 years, I've been the director of pharmacy operations at a large oncology practice located in the Southern United States.

We primarily treat adult oncology and hematology patients, as well as treating patients with iron deficiency anemias due to several different etiologies, which include heavy menstrual bleeding, inflammatory bowel disease, post-bariatric surgery, and cancer induced anemia.

In my experience, treatment options for iron deficiency anemia have evolved so much in recent years.

There are so many options now and no parity among dosing, so really we have to decide what's best for each individual patient.

In my experience, one of the largest bears to maintaining a regimen designed to treat iron deficiency anemia is the actual logistics of getting the patient to the clinic.

If they don't get in to get their entire dose, they run the risk of having worsening symptoms of their iron deficiency anemia.

Additional operational challenges that we have to consider with the treatment of iron deficiency anemia have to do with possibly scheduling a patient anywhere from two to five times to receive their full dose of IV iron.

This can lead to busier clinic days, more stress for the patient, and more stress to our staff.

Monoferric is actually the preferred IV iron product in our clinic and has been for the last couple of years.

Our physicians like the idea that a patient can receive their entire iron dose in a single dose, and we haven't noticed a significant difference in adverse events compared to other IV iron products.

Some of the benefits of a single dose option of Monoferric include the fact that the patient only has to come to the clinic one time to get their full dose of IV iron.

This also reduces the amount of patients that we have to schedule in our clinic leading to less workload and less stress on our nurses.

I certainly consider hypophosphatemia incident rates when determining high dose IV iron product in my clinic.

Knowing that Monoferric has head-to-head data measuring hypophosphatemia published in JAMA, I feel more comfortable recommending it, especially in high risk populations.

In my experience, the Monoferric Patient Solutions program has been excellent in helping improve the patient journey.

From a front office perspective, the quick response times and customized support you receive from Monoferric are a huge help.

I love to see all our nurses educated on the intricacies of treatment, and Monoferric has a comprehensive nurse educator program.

The tools and flow sheets they use are easy to follow and ensure our nurses are prepared to administer Monoferric.

Recently, I had to have a vial replaced for a patient, and I was impressed with the speed and ease of the process.

As a director of pharmacy operations, I choose Monoferric at my practice because it gives our staff and our patients a one dose option to address iron deficiency anemia.

For more information, explore Monoferric.com

I’m Dr Huzefa Bahrain, welcome to Monoferric Moments.

I practice hematology and oncology in Baltimore. We operate an erythropoiesis center where we treat a wide variety of patients with various iron deficiency anemia etiologies. They can range from bariatric surgery patients to heart failure, to pregnancy.

Monoferric is an intravenous iron replacement therapy that can be given in just 1 single dose, delivering 1000 milligrams.

In my experience, we find that for most patients, just 1 dose of 1000 milligrams of Monoferric is sufficient to replace iron stores. If iron deficiency anemia reoccurs, a repeat dose would be necessary.

I use Monoferric in my practice because of its overall combination of 1-dose administration, efficacy, tolerability, and patient support services.

For more information, explore Monoferric.com

I’m Dr Huzefa Bahrain, welcome to Monoferric Moments.

In my experience, we find that for most patients, just 1 dose of 1000 milligrams of Monoferric is sufficient to replenish iron stores.

Looking at all the intravenous iron infusions we’ve administered through clinical trials and commercial patients, Monoferric is observed as having a solid safety profile that is comparable to iron sucrose and is generally well tolerated by the vast majority of patients.

Monoferric has been evaluated in two clinical trials with a total of 3050 patients.

When looking at safety, there was no significant differences in adjudicated serious or severe hypersensitivity reactions between Monoferric and iron sucrose.

Only 0.3 percent of patients reported adjudicated serious or severe hypersensitivity reactions.

Monoferric was also evaluated in the PHOSPHARE study, which was two identical safety trials that were pooled to compare the incidence of hypophosphatemia with Monoferric vs ferric carboxymaltose.

Monoferric demonstrated significantly fewer incidences of hypophosphatemia than ferric carboxymaltose from baseline to day 35.

In the PHOSPHARE study pooled results, only 8.0% of patients treated with Monoferric versus 74.4% of those treated with ferric carboxymaltose were noted to have hypophosphatemia.

For more information, explore Monoferric.com

The The Monoferric Patient Solutions® Program has been helpful to those who have trouble accessing intravenous iron. The program is well coordinated and supportive to the patients and their needs.

There is also the availability of Nurse Educators for infusion staff.